M Pharmaceutical to launch ToConceive in September

2017-07-11 06:50 ET - News Release

Ms. Kim Whittemore reports
M PHARMACEUTICAL INC. PROVIDES UPDATE ON FDA CLEARED OTC PRODUCT, TOCONCEIVE
M Pharmaceutical Inc. has taken important steps to release the innovative, Food and Drug Administration-cleared, over-the-counter product ToConceive to the North American marketplace. The company acquired the global marketing rights to ToConceive in November of 2016 and immediately contracted with Anstice Communications (Anstice) based in Calgary. Anstice, one of Canada's leading integrated communications agencies, has developed new branding, packaging and website for ToConceive, and is assisting in driving information and awareness about ToConceive to the public in advance of its launch to market now anticipated for September, 2017.

"As someone who endured a long and costly fertility journey (emotional, physical and financial), I'm optimistic about any non-invasive option that can help address fertility related issues and do so much earlier in the journey," said Kim Whittemore, a recognized women's sexual health advocate and M Pharmaceutical board member. "The science behind ToConceive is sound and will help many couples avoid more expensive and invasive treatments."

"Anstice is proud to partner with M Pharmaceuticals as it introduces ToConceive to the market," said Sheenah Rogers, founder and chief executive officer of Antsice Communications. "We will be working closely with M Pharma to implement an effective brand strategy and build strong awareness of this innovative new product among consumers."

About M Pharmaceutical Inc.
Formed in early 2015, M Pharmaceutical is a clinical-stage company developing innovative technologies for obesity, weight management, and female health and wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, and assets from 40J's LLC, the company is scheduled to launch its FDA-cleared fertility product branded as ToConceive in September of 2017.
We seek Safe Harbor.